Causaly vs Dozee

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Causaly employs 1-50 people, while Dozee has 50-200 employees.

Dozee has raised $20M in disclosed funding across 0 known rounds. Causaly's funding history is not publicly available.

Dozee holds the higher Awaira Score at 60/100, compared to Causaly's 45/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 15-point gap that reflects meaningful differences in scale or traction.

Causaly was founded by Elias Iosif in 2018. Dozee was founded by Mudit Dandwate in 2015. Visit each company's profile on Awaira for a full founder biography.

Causaly: Causaly built a biomedical AI platform that extracts and maps causal relationships from scientific literature at scale, allowing pharmaceutical researchers and scientists to query cause-and-effect relationships across millions of published papers and clinical documents. The platform used a specialised natural language processing system trained to identify causal assertions in biomedical text, producing a structured knowledge graph of disease mechanisms, drug targets, and biological pathways.\n\nThe company was founded in London in 2018 and was acquired by Elsevier, the academic publishing giant, in 2022. The acquisition gave Elsevier an AI layer to sit atop its vast corpus of scientific publications, enabling researchers using ScienceDirect and other Elsevier products to query causal biological knowledge rather than simply searching for documents. Prior to acquisition, Causaly had built a client base among pharmaceutical R&D teams seeking to accelerate literature review and hypothesis generation.\n\nCausaly represented a niche but strategically important segment of the biomedical AI market: causal reasoning and knowledge graph construction. Its acquisition by Elsevier followed a broader trend of academic publishers acquiring AI startups to enhance their platforms, similar to Wiley acquiring Atypon and Springer Nature building AI discovery tools. The company is now integrated into Elsevier Research Intelligence, extending causal AI capabilities to Elsevier institutional subscribers worldwide. Dozee: Dozee builds a contactless remote patient monitoring system that uses a ballistocardiography sensor placed under a mattress to continuously track heart rate, respiratory rate, blood pressure trends, and sleep quality, transmitting data to an AI analysis platform that generates clinical-grade early warning scores for hospital staff. The system requires no wearables or patient cooperation, enabling continuous monitoring for elderly patients, post-surgical recovery, and ICU step-down units.\n\nThe company raised approximately $20M in Series B funding and has deployed its monitoring systems across hospitals in India and internationally, with evidence of measurable reductions in deterioration events and ICU transfers through early warning. Dozee's central monitoring dashboard allows nursing staff to oversee multiple patients simultaneously with automated deterioration alerts.\n\nContinuous patient monitoring outside of ICU settings is an underserved clinical problem globally, and particularly acute in India where nurse-to-patient ratios in general wards are often insufficient for manual vital sign monitoring. Dozee's contactless approach and AI early warning capability address both the clinical quality and resource efficiency dimensions of this challenge.

Dozee was founded first in 2015, giving it 3 years of additional market experience. Causaly was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Causaly has approximately 1-50 employees, while Dozee has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Causaly and Dozee are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.